AZTA Healthcare

Azenta, Inc.

$37.14+4.47%

Price as of close on Nov 3, 2026 · Financials updated Oct 6, 2026

Basics

Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: United States
Market cap: 1.6B USD
Enterprise value: 1.4B USD
Full-time employees: 2,900

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 1.52 vs a peer median of 0.63)bigger price swings (beta 1.52 vs peers 0.63)
About average: risk (debt, liquidity and share-price swings)risk

Ranks #932 of 1,157 healthcare companies (bottom 20%)

See how it ranks against its peers

Worth knowing

Returning more cash than it generates. Paid out $1.5B vs $17M of free cash flow over the 3 fiscal years to FY Sep 2025.
Azenta returned $1.5B to shareholders over three years, 8787% of the free cash flow it produced. That gap has to be covered by cash reserves or new debt, which can't last indefinitely.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Azenta looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Share count shrinking. Shares outstanding down 42% from September 2022 to August 2026.
Azenta had 42% fewer shares at August 2026 than at September 2022, mainly through buybacks, so each remaining share owns a larger slice of the business.
Loss over 12 months, profit last quarter. Lost money in the 12 months to June 2026, but made a $2.5M profit in the quarter to June 2026.
Azenta reported a net loss over the last twelve months, but its most recent quarter was profitable ($2.5M). One quarter isn't a trend, but it's closer to profitability than the 12-month figure suggests.

StockQuotient Score

33/ 100

Oct 5 34 → Nov 4 33 (-1)

Valuation

Is the price right?

38/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Share count down 5.0%

Valuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-7.6%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield2.4%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsReported value50% base weight · Z-score -0.39Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield0.6%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield92.8%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

28/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 2.9%

Why

Weaker than most peers on:

▼ EPS growth
▼ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

The loss per share widened33% base weight · Z-score -1.20Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth-0.9%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score -0.80Sector median: 0.0584 · MAD: 0.0840

Revenue growth4.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.12Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

27/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Operating margin
▼ ROIC
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-28.6%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -2.93Sector median: 0.0706 · MAD: 0.1217

Return on assets-6.6%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.53Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-10.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.51Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin44.0%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-8.1%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Mixed versus peers:

▲ Debt / equity
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.52

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -2.66Sector median: 0.6250 · MAD: 0.3380

Current ratio2.50×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.06Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.04×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 0.91Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Azenta

Is Azenta getting weaker?: Its latest SEC filing (Aug 6, 2026) got stronger: share count down 5.0%. Its overall score is unchanged at 33/100 since Oct 28, 2026.
How is Azenta valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 38/100 against 1,393 healthcare peers. Earnings yield -7.6% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -7.6% vs peers 1.5% (weaker than 100% of peers).
Is Azenta growing?: More slowly than most of its peers. Growth scores 28/100 against 1,393 healthcare peers. 3-year revenue growth -0.9% vs a peer median of 5.8% (weaker than 73% of peers).3-year revenue growth -0.9% vs peers 5.8% (weaker than 73% of peers).
How profitable is Azenta?: Less profitable than most of its peers. Profitability scores 27/100 against 1,393 healthcare peers. Operating margin -28.6% vs a peer median of 7.1% (weaker than 80% of peers).Operating margin -28.6% vs peers 7.1% (weaker than 80% of peers).
How risky is Azenta?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.04× vs a peer median of 0.22× (stronger than 79% of peers).Debt / equity 0.04× vs peers 0.22× (stronger than 79% of peers). Beta 1.52 vs a peer median of 0.63 (weaker than 88% of peers).Beta 1.52 vs peers 0.63 (weaker than 88% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 6, 2026 · compared with the quarter ended Mar 31, 2026

Got stronger

Share count down 5.0%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	596.5M USD	613.8M USD	+2.9%
Net income (12 months)	−173.3M USD	−122.9M USD	−29.1%
Operating margin	-29.0%	-28.6%	+0.4 pts
Free cash flow (12 months)	30.0M USD	9.9M USD	−67.1%
Cash	234.0M USD	189.7M USD	−19.0%
Shares outstanding	46.1M	43.8M	−5.0%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Instruments & Supplies · 25 companies

Valuations in Medical Instruments & Supplies are near the bottom of their range since Jul 2018.

18% of months since Jul 2018 were valued lower than now.
0% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +17% vs the whole market, against a usual +86%.

Jul 2018Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY Sep 2021	FY Sep 2022	FY Sep 2023	FY Sep 2024	FY Sep 2025	Change
Gross margin	47.5%	46.0%	43.4%	44.4%	45.5%	▲ 1.1 pts
Operating margin	-6.1%	-4.5%	-11.1%	-8.9%	-4.5%	▲ 4.4 pts
Net margin	21.6%	384.0%	-2.7%	-28.8%	-9.4%	▲ 19 pts
Return on assets (ROA)	6.1%	57.4%	-0.5%	-7.9%	-2.7%	▲ 5.1 pts
Return on equity (ROE)	8.4%	63.4%	-0.6%	-9.3%	-3.2%	▲ 6.1 pts
Free cash flow margin	18.9%	-97.1%	-6.1%	2.2%	6.5%	▲ 4.3 pts
Current ratio	2.25×	10.67×	6.73×	4.04×	2.98×	▼ 26%
Quick ratio	2.08×	10.30×	6.12×	3.70×	2.66×	▼ 28%
Debt to equity	0.04×	—	—	—	—	—
Interest coverage	-15.26×	-5.39×	—	—	—	—

AZTA price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 1.52 vs a peer median of 0.63)bigger price swings (beta 1.52 vs peers 0.63)

About average: risk (debt, liquidity and share-price swings)risk

Ranks #932 of 1,157 healthcare companies (bottom 20%)

See how it ranks against its peers

Worth knowing

Returning more cash than it generates. Paid out $1.5B vs $17M of free cash flow over the 3 fiscal years to FY Sep 2025.

Azenta returned $1.5B to shareholders over three years, 8787% of the free cash flow it produced. That gap has to be covered by cash reserves or new debt, which can't last indefinitely.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Azenta looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Share count shrinking. Shares outstanding down 42% from September 2022 to August 2026.

Azenta had 42% fewer shares at August 2026 than at September 2022, mainly through buybacks, so each remaining share owns a larger slice of the business.

Loss over 12 months, profit last quarter. Lost money in the 12 months to June 2026, but made a $2.5M profit in the quarter to June 2026.

Azenta reported a net loss over the last twelve months, but its most recent quarter was profitable ($2.5M). One quarter isn't a trend, but it's closer to profitability than the 12-month figure suggests.

Questions investors ask about Azenta

Is Azenta getting weaker?

Its latest SEC filing (Aug 6, 2026) got stronger: share count down 5.0%. Its overall score is unchanged at 33/100 since Oct 28, 2026.

How is Azenta valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 38/100 against 1,393 healthcare peers. Earnings yield -7.6% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -7.6% vs peers 1.5% (weaker than 100% of peers).

Is Azenta growing?

More slowly than most of its peers. Growth scores 28/100 against 1,393 healthcare peers. 3-year revenue growth -0.9% vs a peer median of 5.8% (weaker than 73% of peers).3-year revenue growth -0.9% vs peers 5.8% (weaker than 73% of peers).

How profitable is Azenta?

Less profitable than most of its peers. Profitability scores 27/100 against 1,393 healthcare peers. Operating margin -28.6% vs a peer median of 7.1% (weaker than 80% of peers).Operating margin -28.6% vs peers 7.1% (weaker than 80% of peers).

How risky is Azenta?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.04× vs a peer median of 0.22× (stronger than 79% of peers).Debt / equity 0.04× vs peers 0.22× (stronger than 79% of peers). Beta 1.52 vs a peer median of 0.63 (weaker than 88% of peers).Beta 1.52 vs peers 0.63 (weaker than 88% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

596.5M USD

613.8M USD

+2.9%

Net income (12 months)

−173.3M USD

−122.9M USD

−29.1%

Operating margin

-29.0%

-28.6%

+0.4 pts

Free cash flow (12 months)

30.0M USD

9.9M USD

−67.1%

Cash

234.0M USD

189.7M USD

−19.0%

Shares outstanding

46.1M

43.8M

−5.0%

Key ratios

FY Sep 2021

FY Sep 2022

FY Sep 2023

FY Sep 2024

FY Sep 2025

Change

Gross margin

47.5%

46.0%

43.4%

44.4%

45.5%

▲ 1.1 pts

Operating margin

-6.1%

-4.5%

-11.1%

-8.9%

-4.5%

▲ 4.4 pts

Net margin

21.6%

384.0%

-2.7%

-28.8%

-9.4%

▲ 19 pts

Return on assets (ROA)

6.1%

57.4%

-0.5%

-7.9%

-2.7%

▲ 5.1 pts

Return on equity (ROE)

8.4%

63.4%

-0.6%

-9.3%

-3.2%

▲ 6.1 pts

Free cash flow margin

18.9%

-97.1%

-6.1%

2.2%

6.5%

▲ 4.3 pts

Current ratio

2.25×

10.67×

6.73×

4.04×

2.98×

▼ 26%

Quick ratio

2.08×

10.30×

6.12×

3.70×

2.66×

▼ 28%

Debt to equity

0.04×

—

Interest coverage

-15.26×

-5.39×

—